Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Ergoloid

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Ergoloid
Combination of
DihydroergocristineErgotalkaloid
DihydroergocornineErgot alkaloid
alpha-DihydroergocryptineErgot alkaloid
beta-DihydroergocryptineErgot alkaloid
Clinical data
Other namesCo-dergocrine, dihydroergotoxine
Pregnancy
category
  • Contraindicated
Routes of
administration
Oral, parenteral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability25%
Protein binding98–99%
Metabolism50%
Eliminationhalf-life3.5 hours
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
ChEBI
CompTox Dashboard(EPA)
ECHA InfoCard100.158.718Edit this at Wikidata
 ☒NcheckY (what is this?)  (verify)

Ergoloid mesylates (USAN),co-dergocrine mesilate (BAN) ordihydroergotoxine mesylate, trade nameHydergine, is a mixture of themethanesulfonatesalts of threedihydrogenatedergotalkaloids (dihydroergocristine,dihydroergocornine, andalpha- andbeta-dihydroergocryptine).

It was developed byAlbert Hofmann (the discoverer ofLSD) forSandoz (now part ofNovartis).

Medical uses

[edit]

It has been used to treatdementia and age-related cognitive impairment (such as inAlzheimer disease),[1] as well as to aid in recovery afterstroke.

A systematic review published in 1994 found little evidence to support the use of ergoloid mesylates, concluding only that potentially effective doses may be higher than those currently approved in dementia treatment.[2]

Ergoloid Mesylate Tablets USP for sublingual use contain 1 mg of Ergoloid Mesylates USP, a mixture of the methanesulfonate salt of the following hydrogenated alkaloids: Dihydroergocornine mesylate 0.333 mg, Dihydroergocristine mesylate 0.333 mg, Dihydroergocryptine mesylate 0.333 mg.[3]

It has been used to treathyperprolactinemia (high prolactin levels).[4]

The use of ergoloid alkaloids for dementia has been surrounded with uncertainties. In 2000, a systematicCochrane review concluded that hydergine was well tolerated and showed significant treatment effects when assessed by either global ratings or comprehensive rating scales. The small number of available trials for analysis, however, limited the ability to demonstrate statistically significant moderating effects in certain subgroups (e.g. younger age, higher dosage, Alzheimer disease).[5]

Contraindications

[edit]

Ergoloid is contraindicated in individuals who have previously shown hypersensitivity to the drug. They are also contraindicated in patients who have psychosis, acute or chronic, regardless ofetiology.[6] Specific drug interactions are unknown but it has been claimed that there are multiple potential interactions.[6]

Side effects

[edit]

Adverse effects are minimal. The most common include transient, dose dependent nausea and gastrointestinal disturbances,[7] and sublingual irritation with SL tablets. Other common side effects include:[6][8]

As a result of the last-mentioned effects, the use ofergoline derivatives for the treatment of blood circulation disorders, memory problems, sensation problems and the treatment of migraine is no longer permitted in some EU countries because the risks are believed to outweigh any benefits.[9] However, this concern may be unnecessarily suppressing the use of ergoline medications.[11]

Pharmacology

[edit]

Mechanism of action

[edit]

Despite the fact that this drug has been used in the treatment of dementia for many years, itsmechanism of action is still not clear.[7] It stimulatesdopaminergic andserotonergic receptors and blocks alpha-adrenoreceptors.[12] Current studies imply that the major effect of hydergine may be the modulation of synaptic neurotransmission rather than solely increasing blood flow as was once thought.[13] A prominent feature that accompanies aging is an increase inmonoamine oxidase (MAO) levels.[14] This results in decreased availability ofcatecholamines in the synaptic cleft. In one study, an interaction between age and hydergine treatment was observed in thehypothalamus,hippocampus andcerebellum. The hydergine effect was more pronounced in the aged group in the hypothalamus and cerebellum, and more pronounced in the adult in thehippocampus. These findings imply that increased brain MAO activity in aging can be modified by hydergine treatment in some brain regions.

Chemistry

[edit]

The four constituents differ only in which of fourproteinogenic amino acids is used inbiosynthesis:[15]

CompoundAmino acid
DihydroergocristinePhenylalanine
DihydroergocornineValine
alpha-DihydroergocryptineLeucine
beta-DihydroergocryptineIsoleucine

Society and culture

[edit]

Brand names

[edit]

Brand names include Hydergine, Hydergina, Gerimal, Niloric, Redizork, Alkergot, Cicanol, Redergin, and Hydrine.

References

[edit]
  1. ^Flynn BL, Ranno AE (February 1999). "Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives".The Annals of Pharmacotherapy.33 (2):188–197.doi:10.1345/aph.17172.PMID 10084415.S2CID 12524454.
  2. ^Schneider LS, Olin JT (August 1994). "Overview of clinical trials of hydergine in dementia".Archives of Neurology.51 (8):787–798.doi:10.1001/archneur.1994.00540200063018.PMID 8042927.
  3. ^"Ergoloid".Drugs.com. Archived fromthe original on 12 June 2021. Retrieved2 August 2013.
  4. ^Bankowski BJ, Zacur HA (June 2003). "Dopamine agonist therapy for hyperprolactinemia".Clinical Obstetrics and Gynecology.46 (2):349–362.doi:10.1097/00003081-200306000-00013.PMID 12808385.S2CID 29368668.
  5. ^Olin J, Schneider L, Novit A, Luczak S (2001)."Hydergine for dementia".The Cochrane Database of Systematic Reviews (2): CD000359.doi:10.1002/14651858.CD000359.PMC 6769017.PMID 11405961.
  6. ^abc"Drugs to Treat Alzheimer's Disease".Journal of Psychosocial Nursing & Mental Health Services.52 (4):21–22. April 2014.
  7. ^abSchiff PL (October 2006)."Ergot and its alkaloids".American Journal of Pharmaceutical Education.70 (5): 98.doi:10.5688/aj700598.PMC 1637017.PMID 17149427.
  8. ^Majumdar A, Mangal NS (July 2013)."Hyperprolactinemia".Journal of Human Reproductive Sciences.6 (3):168–175.doi:10.4103/0974-1208.121400.PMC 3853872.PMID 24347930.
  9. ^ab"Ergot derivatives: restricted use"(PDF).WHO Drug Information.27 (3): 225. 2013.[dead link]
  10. ^Helsen V, Decoutere L, Spriet I, Fagard K, Boonen S, Tournoy J (2013)."Ergotamine-induced pleural and pericardial effusion successfully treated with colchicine".Acta Clinica Belgica.68 (2):113–115.doi:10.2143/ACB.3138.PMID 23967719.S2CID 24802394.
  11. ^Zajdel P, Bednarski M, Sapa J, Nowak G (April 2015). "Ergotamine and nicergoline - facts and myths".Pharmacological Reports.67 (2):360–363.doi:10.1016/j.pharep.2014.10.010.PMID 25712664.S2CID 22768662.
  12. ^Markstein R (1985). "Hydergine: interaction with the neurotransmitter systems in the central nervous system".Journal de Pharmacologie.16 (Suppl 3):1–17.PMID 2869188.
  13. ^Rowell PP, Larson BT (July 1999). "Ergocryptine and other ergot alkaloids stimulate the release of [3H]dopamine from rat striatal synaptosomes".Journal of Animal Science.77 (7):1800–1806.doi:10.2527/1999.7771800x.PMID 10438027.
  14. ^Kennedy GJ, Tanenbaum S (Dec 2000). "Suicide and aging: international perspectives".The Psychiatric Quarterly.71 (4):345–362.doi:10.1023/a:1004636307592.PMID 11025912.S2CID 35607526.
  15. ^Steinhilber D, Schubert-Zsilavecz M, Roth HJ (2005).Medizinische Chemie (in German). Stuttgart, Germany: Deutscher Apotheker Verlag. p. 142.ISBN 3-7692-3483-9.

External links

[edit]
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Flavonoids
Imidazoles
Kava constituents
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Pyrazolopyridines
Quinazolinones
Volatiles/gases
Others/unsorted
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Lysergamides
Ergopeptines
Clavines
Other
ergolines
Related
compounds
Natural
sources
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ergoloid&oldid=1280245879"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp